• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/18/26 4:42:27 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    mo-20260513
    false000076418000007641802026-05-132026-05-130000764180mo:CommonStock0.3313ParValueMember2026-05-132026-05-130000764180mo:CommonStock2.200NotesDue2027Member2026-05-132026-05-130000764180mo:CommonStock3.125NotesDue2031Member2026-05-132026-05-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     ____________________________________________________________________________________________________________
    FORM 8-K
    ________________________________________________________________________________________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 13, 2026
    ________________________________________________________________________________________________________________
    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia  1-08940  13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (804) 274-2200
    _______________________________________________________________________________________________________________
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
                   Title of each class               
    Trading SymbolsName of each exchange on which registered
    Common Stock, $0.33 1/3 par value
    MONew York Stock Exchange
    2.200% Notes due 2027
    MO27New York Stock Exchange
    3.125% Notes due 2031
    MO31New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Compensation of New Chief Executive Officer and New Chief Financial Officer
    As previously reported, Salvatore Mancuso was elected Chief Executive Officer (“CEO”) of Altria Group, Inc. (“Altria”) effective upon the conclusion of Altria’s Annual Meeting of Shareholders held on May 14, 2026 (the “Annual Meeting”). As a result of his election, Mr. Mancuso became a salary band A employee. On May 13, 2026, the Compensation and Talent Development Committee of Altria’s Board of Directors (the “Compensation Committee”) set his annual base salary as of May 14, 2026 at $1,350,000. Also in connection with his election, the Compensation Committee approved for Mr. Mancuso a grant of 40,634 restricted stock units (“RSUs”) and 37,246 performance stock units (“PSUs”). The RSUs and any PSUs earned will vest on May 15, 2031, five years after the grant date. The actual number of PSUs that will be earned will range between 0% and 200% of target, depending on actual performance during the 2026 - 2028 performance period. Effective May 14, 2026 as a salary band A employee, Mr. Mancuso’s annual incentive award plan target is 175% of base salary and his annual equity award target is $8.5 million. Additionally, his Long-Term Incentive Plan (“LTIP”) award target for the 2024 – 2026 plan is 260% of salary. His LTIP award targets for the 2025 – 2027 and 2026 – 2028 plans are $4.0 million and $4.0 million, respectively. The award targets were established by the Compensation Committee for salary band A employees at the beginning of each performance period. The awards under the annual incentive award plan and the LTIP will be pro-rated based on his time in each salary band, and, in the case of the 2024 – 2026 LTIP, his salary, during the performance periods. The Compensation Committee also approved an allowance of $125,000 for the period from May 14, 2026 to December 31, 2026 for Mr. Mancuso’s personal use of Altria aircraft. The Compensation Committee considered the potential value of Mr. Mancuso’s personal aircraft usage in determining the other components of his total compensation. Altria will also provide Mr. Mancuso upgrades and monitoring for his residential security system in addition to cybersecurity monitoring.
    Also as previously reported, Heather A. Newman was elected Executive Vice President and Chief Financial Officer of Altria effective upon the conclusion of the Annual Meeting. As a result of her election, Ms. Newman became a salary band B employee. On May 13, 2026, the Compensation Committee set her annual base salary as of May 14, 2026 at $800,000. As a salary band B employee, Ms. Newman’s annual incentive award plan target is 100% of base salary and her annual equity award target is $2.25 million. Additionally, her LTIP award target for the 2024 – 2026 plan is 140% of salary. Her LTIP award targets for the 2025 – 2027 and 2026 – 2028 plans are $1.25 million and $1.5 million, respectively. The award targets were established by the Compensation Committee for salary band B employees at the beginning of each performance period. The awards under the annual incentive award plan and the LTIP will be pro-rated based on her time in each salary band, and, in the case of the 2024 – 2026 LTIP, her salary, during the performance periods.
    Retirement Arrangements with Former CEO
    As previously reported, William F. Gifford, Jr. retired as Altria’s CEO effective upon the conclusion of the Annual Meeting. On May 13, 2026 the Compensation Committee approved a payment under the annual incentive award plan of $995,822, reflecting his award target of 175% of his salary on March 1, 2026, pro-rated through May 14, 2026. The Compensation Committee also approved pro-rated payments under the 2024 – 2026 and 2025 – 2027 LTIPs that will be based on a company performance rating using Altria’s actual business performance for each three-year performance cycle, as determined by the Compensation Committee after the conclusion of each applicable cycle in 2027 and 2028. His pro-rated award target for the 2024 – 2026 LTIP is $3,030,284 and for the 2025 – 2027 LTIP is $1,822,831. There is no guarantee of any payment under the 2024 – 2026 LTIP or 2025 – 2027 LTIP, which, if earned, will be made following the end of the applicable performance cycle and pro-rated through May 14, 2026. Under the terms of the applicable award agreements, Mr. Gifford will forfeit all his unvested RSU and PSU awards, specifically those granted in 2024 and 2025, immediately upon his retirement. Mr. Gifford did not receive an annual equity award in 2026. Additionally, under the terms of the 2026 – 2028 LTIP, Mr. Gifford forfeited eligibility for payment.
    On May 13, 2026, the Compensation Committee approved cash payments to Mr. Gifford for (i) his unvested 2024 RSU award (88,718 RSUs) and unvested 2025 RSU award (84,433 RSUs) and (ii) his unvested 2024 PSU award (85,883 PSUs) and unvested 2025 PSU award (81,107 PSUs), in each case pro-rated for the period that Mr. Gifford worked during the applicable vesting periods. The values of the RSU payments will be determined using the average closing price of Altria’s common stock on the New York Stock Exchange (“NYSE”) on each of the 20 trading days immediately preceding and including May 14, 2026. The values of the PSU payments will be determined based on the closing price of Altria’s common stock on the NYSE on the day before the vest date, adjusted by the PSU performance rating as determined by the Compensation Committee after the conclusion of each three-year performance cycle ending in 2026 and 2027. The cash payment for the RSUs will be made in the fourth quarter of 2026; the payments for the PSUs, if any, will be made after the conclusion of the applicable performance cycles ending in 2026 and 2027. Based on the average closing price of Altria’s common stock on the NYSE on each of the 20 trading days immediately preceding and including May 14, 2026, the aggregate cash payment for the RSUs is $6,859,062 and the aggregate cash payment for the PSUs at a target business performance, which also includes target dividend equivalents, is $7,837,712. The final values of the PSU payments will be determined at a later date based on the valuation methods noted above and Altria’s
    2


    actual business performance. Mr. Gifford will also be entitled to payments and benefits generally available to employees under the terms of Altria’s benefit plans.
    The foregoing treatment is consistent with the Guidelines on Compensation Treatment for Departing Executive Officers, adopted by the Compensation Committee in 2021, as described in the “Compensation Discussion and Analysis” section of Altria’s proxy statement for its 2021 Annual Meeting of Shareholders (filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021). Altria’s annual incentive award program and other executive compensation programs are more fully described in the “Compensation Discussion and Analysis” section of Altria’s proxy statement for the Annual Meeting (filed with the SEC on April 2, 2026). Mr. Gifford will remain subject to the restrictive covenants and other terms of the Confidentiality and Non-Competition Agreement between Altria and Mr. Gifford with the 18-month post-employment restriction period referenced in paragraphs 6 and 7 of that agreement commencing upon the expiration or earlier termination of the Consulting Agreement described below. A copy of the form of the Confidentiality and Non-Competition Agreement was filed previously as Exhibit 10.3 to Altria’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
    In addition, in connection with Mr. Gifford’s retirement, the aircraft time sharing agreement, dated February 23, 2023 (the “Time Sharing Agreement”) between Mr. Gifford and Altria Client Services LLC has been terminated effective May 14, 2026. A copy of the Time Sharing Agreement was filed previously as Exhibit 10.44 to Altria’s Annual Report on Form 10-K for the year ended December 31, 2025.
    Consulting Agreement with Former CEO
    Mr. Gifford will serve as a consultant to Altria and its Board of Directors following his retirement to help facilitate an effective CEO and CFO transition and as a resource to the Board Directors and the executive leadership team. Pursuant to the Consulting Agreement, dated May 15, 2026, between Mr. Gifford and Altria, Mr. Gifford will provide consulting services from May 15, 2026 through December 31, 2026, unless terminated earlier as set forth in the Consulting Agreement, and will be compensated for his services as a consultant at a rate of $250,000 per month, through December 31, 2026. The monthly payment for May 2026 will be pro-rated. Mr. Gifford will not receive any other compensation in connection with his services as a consultant. A copy of the Consulting Agreement is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference in this Item 5.02.
    Item 5.07.    Submission of Matters to a Vote of Security Holders.
    There were 1,364,466,571 shares of Altria’s common stock represented in person or by proxy at the Annual Meeting, constituting 81.64% of outstanding shares on March 25, 2026, the record date for the Annual Meeting. The matters voted upon at the Annual Meeting and the final voting results are set forth below:
    Proposal 1:    Election of 10 Directors.
    NameForAgainstAbstainBroker Non-Vote
    Ian L.T. Clarke1,013,287,2038,238,9103,752,218339,188,240
    Marjorie M. Connelly1,008,048,87413,600,2163,629,241339,188,240
    R. Matt Davis1,013,953,3697,535,2133,789,749339,188,240
    Debra J. Kelly-Ennis992,663,77929,046,5493,568,003339,188,240
    Salvatore Mancuso1,015,072,3876,516,6673,689,277339,188,240
    Kathryn B. McQuade994,449,27227,294,8773,534,182339,188,240
    Virginia E. Shanks1,013,051,3918,667,0123,559,928339,188,240
    Richard S. Stoddart1,014,437,9777,088,2283,752,126339,188,240
    Ellen R. Strahlman1,012,835,3598,722,4393,720,533339,188,240
    M. Max Yzaguirre1,013,302,7578,247,3653,728,209339,188,240
    All nominees were duly elected as directors of Altria.
    Proposal 2:    Ratification of the Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026.
    ForAgainstAbstain
    1,312,899,22246,339,0415,228,308
    The selection of the independent registered public accounting Firm was ratified.
    3


    Proposal 3:    Non-Binding Advisory Vote to Approve the Compensation of Altria’s Named Executive Officers.
    ForAgainstAbstainBroker Non-Vote
    977,966,53338,503,7668,808,032339,188,240
    The proposal was approved on an advisory basis.

    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits
    10.1
    Consulting Agreement, dated May 15, 2026, between Altria Group, Inc. and William F. Gifford, Jr.
    104
    Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

    4



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ALTRIA GROUP, INC.
    By:/s/ MARY C. BIGELOW
    Name:Mary C. Bigelow
    Title:Vice President, Corporate Secretary and
    Associate General Counsel
                            

    DATE:    May 18, 2026

    5
    Get the next $MO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    1/9/2026$63.00Neutral → Buy
    UBS
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    More analyst ratings

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/28/26 2:31:24 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R sold $145,118 worth of shares (2,000 units at $72.56), decreasing direct ownership by 7% to 25,102 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/28/26 2:31:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 2,571 shares, increasing direct ownership by 10% to 27,102 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/18/26 2:31:49 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Neutral to Buy and set a new price target of $63.00

    1/9/26 8:23:08 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    SEC Form SD filed by Altria Group Inc.

    SD - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/28/26 11:07:45 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 10-K/A filed by Altria Group Inc.

    10-K/A - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/27/26 2:42:37 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/18/26 4:42:27 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Smokeless Tobacco Company Announces Plan to Modernize Manufacturing Footprint Through Facility Relocation

    U.S. Smokeless Tobacco Company LLC (USSTC), a subsidiary of Altria Group, Inc. (NYSE:MO), today announced plans to consolidate certain operations as part of a long-term strategy to modernize its manufacturing footprint and drive operational efficiencies. USSTC will transition manufacturing operations from its Nashville, Tennessee plant to a new facility to be constructed on an existing campus in Hopkinsville, Kentucky. Production in Nashville will wind down gradually, with operations expected to conclude in early 2028. This phased approach is designed to support continuity of operations and a smooth transition for employees. "Modernizing our manufacturing capabilities is essential to po

    5/21/26 4:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2026 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2026 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer (CEO), addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Appointment of CEO Following today's Annual Meeting, Sal Mancuso succeeded Billy Gifford as Altria's CEO. At the end of 2025, Billy Gifford announced his decision to retire after more than 30 years of distinguished service with the Altria family of companies. "Sal is immensely qualified to lead Altria, having served in numerous leadership positions during his more than 30-y

    5/14/26 2:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2026 Annual Meeting of Shareholders

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2026 Annual Meeting of Shareholders ("2026 Annual Meeting" or "meeting") on Thursday, May 14, 2026 at 9:00 a.m. Eastern Time. The 2026 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2026 Annual Meeting record date (March 25, 2026) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2026 Proxy Statement. If you are not a sharehold

    5/1/26 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Reports 2026 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2026 first-quarter business results and reaffirms our guidance for 2026 full-year adjusted diluted earnings per share (EPS). "We delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "Our highly cash-generative businesses supported significant returns to shareholders through dividends and share repurchases, while we continued to invest in support of our Vision." "Our smokeable products segment generated strong income growth. Marlboro strengthened its position in the premium segment, and PM USA continued to execute its total portfolio strategy w

    4/30/26 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on April 30, 2026 to shareholders of record as of March 25, 2026. The ex-dividend date is March 25, 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260225648687/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    2/26/26 1:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Fourth-Quarter and Full-Year Results; Provides 2026 Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 fourth-quarter and full-year business results and provides our guidance for 2026 full-year adjusted diluted earnings per share (EPS). "2025 was a year of continued momentum for Altria, marked by strong financial performance, strategic progress across our smoke-free portfolio, new relationships in support of our long-term growth goals and significant cash returns to shareholders," said Billy Gifford, Altria's Chief Executive Officer. "For the full year, we grew adjusted diluted earnings per share by 4.4% and returned $8 billion to shareholders through dividends and share repurchases combined." "We expect to deliver 2026 full-year adjust

    1/29/26 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Holds 2026 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2026 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer (CEO), addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Appointment of CEO Following today's Annual Meeting, Sal Mancuso succeeded Billy Gifford as Altria's CEO. At the end of 2025, Billy Gifford announced his decision to retire after more than 30 years of distinguished service with the Altria family of companies. "Sal is immensely qualified to lead Altria, having served in numerous leadership positions during his more than 30-y

    5/14/26 2:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director George Muñoz from Board of Directors

    Altria Group, Inc. (Altria) (NYSE:MO) -- George Muñoz, a director of Altria since 2004, notified Altria of his decision to retire from service on our Board of Directors (Board) following the completion of his current term. Consequently, Mr. Muñoz will not stand for re-election to our Board at our 2026 Annual Meeting of Shareholders, which Altria anticipates holding on May 14, 2026. "George has made extensive and significant contributions to Altria over more than 20 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank George for his long-standing and valuable service and wish him the very best upon his retirement." Mr. Muñoz is Chair of the Compensation and Ta

    10/9/25 8:35:00 AM ET
    $LAUR
    $MO
    Other Consumer Services
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care